134 related articles for article (PubMed ID: 19904462)
1. Neuroblastoma screening in Japan: population-based cohort study and future aspects of screening.
Hiyama E
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):88-4. PubMed ID: 19904462
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
3. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan.
Yamamoto K; Ohta S; Ito E; Hayashi Y; Asami T; Mabuchi O; Higashigawa M; Tanimura M
J Clin Oncol; 2002 Mar; 20(5):1209-14. PubMed ID: 11870162
[TBL] [Abstract][Full Text] [Related]
4. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
5. Mass screening for neuroblastoma and mortality in birth cohorts.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
[TBL] [Abstract][Full Text] [Related]
6. Screening for neuroblastoma: a 9-year birth cohort-based study in Niigata, Japan.
Asami T; Otabe N; Wakabayashi M; Kakihara T; Uchiyama M; Asami K
Acta Paediatr; 1995 Oct; 84(10):1173-6. PubMed ID: 8563231
[TBL] [Abstract][Full Text] [Related]
7. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of nationwide screening program for neuroblastoma in Japan.
Hisashige A;
Glob J Health Sci; 2014 Apr; 6(4):94-106. PubMed ID: 25001552
[TBL] [Abstract][Full Text] [Related]
9. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.
Berthold F; Spix C; Erttmann R; Hero B; Michaelis J; Treuner J; Ernst A; Schilling FH
JNCI Cancer Spectr; 2021 Jul; 5(4):. PubMed ID: 34240006
[TBL] [Abstract][Full Text] [Related]
11. Mass screening for neuroblastoma by HPLC and by non-HPLC: a review.
Nishi M; Miyake H; Hanai J; Fujita K; Hatae Y; Takeda T
Oncol Rep; 1998; 5(6):1399-402. PubMed ID: 9769376
[TBL] [Abstract][Full Text] [Related]
12. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan.
Ajiki W; Tsukuma H; Oshima A; Kawa K
Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening.
Honjo S; Doran HE; Stiller CA; Ajiki W; Tsukuma H; Oshima A; Coleman MP
Int J Cancer; 2003 Feb; 103(4):538-43. PubMed ID: 12478672
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
15. Neuroblastoma screening in infants postponed after the sixth month of age: a trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features.
Kerbl R; Urban CE; Ladenstein R; Ambros IM; Spuller E; Mutz I; Amann G; Kovar H; Gadner H; Ambros PF
Med Pediatr Oncol; 1997 Jul; 29(1):1-10. PubMed ID: 9142198
[TBL] [Abstract][Full Text] [Related]
16. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B; Brodeur GM
Eur J Cancer; 1997 Oct; 33(12):2106-12. PubMed ID: 9516863
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma of the urinary bladder, preclinically detected by mass screening.
Yokoyama S; Hirakawa H; Ueno S; Yabe H; Hiraoka N
Pediatrics; 1999 May; 103(5):e67. PubMed ID: 10224211
[TBL] [Abstract][Full Text] [Related]
18. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
Suita S
J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
[TBL] [Abstract][Full Text] [Related]
19. Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future aspects.
Sawada T; Sugimoto T; Tanaka T; Kawakatsu H; Ishii T; Matsumura T; Horii Y
Med Pediatr Oncol; 1987; 15(1):14-7. PubMed ID: 3561327
[TBL] [Abstract][Full Text] [Related]
20. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
